Windward Bio Group has completed its public market debut after pricing an initial public offering at $17 per share and raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi.
The clinical-stage biotechnology company began trading on the Nasdaq Global Select Market on November 13, 2026 and ended its first day with a market capitalization of approximately $1.69 billion.
Windward sold approximately 10.29 million ordinary shares in the offering.
The Basel, Switzerland-based company was founded in 2024 by serial biotechnology entrepreneur Luca Santarelli, M.D., and his team. Santarelli previously helped build VectivBio and Therachon, both of which were ultimately acquired.
Windward has raised $365 million since its formation, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026.
Pivotal bioVenture Partners China has invested in the company through each financing round from its early formation through the public listing.
Windward is developing ultra-long-acting antibody treatments for respiratory and dermatologic diseases including asthma, chronic obstructive pulmonary disease and atopic dermatitis.
Its lead program, WIN378, is a fully human monoclonal antibody targeting thymic stromal lymphopoietin.
WIN378 is currently being evaluated in the Phase 2/3 POLARIS-1 asthma study and the Phase 2 SIRIUS COPD trial. The drug is being developed for twice-yearly dosing, compared with the once-every-four-weeks schedule of currently approved treatments in the category.
Windward reported positive interim Phase 2 data in September 2026 supporting twice-yearly dosing of WIN378 in asthma.
Its pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 that is currently in Phase 1 development.
Global rights outside Greater China and certain Asian markets to both programs were licensed from Chinese biopharmaceutical companies.
Windward plans to use IPO proceeds to support clinical development of WIN378 and WIN027, advance additional bispecific antibody programs and fund working capital and general corporate purposes.
The company expects top-line Phase 2 asthma data for WIN378 in the first half of 2027, Phase 2 COPD data in the second half of 2027 and Phase 3 asthma data in the first half of 2029.

